Isto Biologics
PrivateLast Round
Buyout/LBO
Sep 17, 2025
Est. Valuation
$1B
Total Funding Raised
$37.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Isto Biologics is a biotechnology company that manufactures orthobiologic medical devices, including autologous concentration systems, allografts, and biosynthetic bone grafts, for use in spine, orthopedics, and sports medicine.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Isto Biologics Comparables
Compare Isto Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Royal Biologics | 79% | |
| Xtant Medical Holdings | 79% | |
| VIVEX Biologics | 78% |
Isto Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Buyout/LBO | Sep 17, 2025 | ||||
| M&A | Oct 25, 2023 | ||||
| Buyout/LBO | Jun 3, 2016 | ||||
| Debt | Mar 18, 2014 | ||||
| Growth Equity | Oct 25, 2007 | ||||
Series E | Aug 1, 2007 |
Isto Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DW Healthcare Partners | Growth Equity |
| EQT Life Sciences | Series E, Series D |
| Mid-America Transplant Services | Series E, Series D |
| Thompson Street Capital Partners | Buyout/LBO, M&A |
| Keensight Capital | Buyout/LBO |
| Alafi Capital | Series E, Series D |
| Ascension Ventures | Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 43, 331% of headcount.
- Sep 17, 2025
$1.0B round led by Keensight Capital
Recent news
Latest coverage and updates
- acquiresAug 4, 2026
On Aug 4th '26, Isto Biologics completes its $60.7M acquisition of Novabone in Massachusetts, expanding its synthetic bone graft portfolio and international reach.
Isto Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Isto Biologics's valuation, stock price, and market status.
Is Isto Biologics a public or private company?
Isto Biologics is a private company.
What is the current stock price of Isto Biologics?
Isto Biologics is a private company, so its shares have no public market price. Caplight tracks Isto Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Isto Biologics worth (valuation)?
Isto Biologics's valuation is estimated at $1.0B based on funding round data.
Can I buy Isto Biologics stock?
Isto Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Isto Biologics's last funding round?
Isto Biologics's most recent funding round was Buyout/LBO on September 17, 2025.
Who are the main investors in Isto Biologics?
Key investors in Isto Biologics include DW Healthcare Partners, Thompson Street Capital Partners, Keensight Capital.
Will Isto Biologics IPO soon?
No public IPO plans have been announced for Isto Biologics.
How can I track Isto Biologics secondary market activity?
Caplight tracks bids, offers, and trades in Isto Biologics's shares on secondary markets.